Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008

Diabetic Medicine

Volumn 27, Issue 7, 2010, Pages 744-752

  Currie, C J ^a   Peters, J R ^b   Evans, M ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

costs; diabetes; drugs; epidemiology; trends

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; GLITAZONE DERIVATIVE; GUAR GUM; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; NEUTRAL INSULIN; PEPTIDOMIMETIC AGENT;

ARTICLE; BUDGET; DRUG COST; GEOGRAPHIC DISTRIBUTION; HUMAN; PRESCRIPTION; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; RISK REDUCTION BEHAVIOR;

EID: 77954270250     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02849.x     Document Type: Article

References (19)

1. International Diabetes Federation. The Diabetes Atlas, 3rd edn.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
3. Department of Health. National Service Framework for People with Diabetes.
4. NICE. Clinical guidance. Available at http://www.nice.org.uk/guidance/ index.jsp?action=ByType&type=2&status=3&p=off Last accessed 11 June 2009.
5. McLean G, Guthrie B, Sutton M. Differences in the quality of primary medical care for CVD and diabetes across the NHS: evidence from the quality and outcomes framework. BMC Health Serv Res 2007 7 : 74.
6. NHS Information Centre for Health and Social Care. PACT Data for England. Available at http://www.ic.nhs.uk/default.asp?sID= 1172577414129&sPublicationID=1239718155461&sDocID=4973 Last accessed 11 June 2009.
7. NHS Northern Ireland. PACT Data for Northern Ireland. Available at http://www.centralservicesagency.com/files/statistics/file/PCT2008.xls Last accessed 11 June 2009.
8. NHS Scotland. PACT Data for Scotland. Available at http://www. isdscotland.org/isd/servlet/FileBuffer?namedFile=PCA%202008.xls& pContentDispositionType=attachment Last accessed 11 June 2009.
9. NHS Wales. PACT Data for Wales. Available at http://www.wales.nhs.uk/ sites3/docopen.cfm?orgid=428&id=117449&A03B1E2D-1143-E756- 5CD9AAFEAC8087BD Last accessed 11 June 2009.
10. Morgan CL, Peters JR, Currie CJ. The changing prevalence of diagnosed diabetes and its associated vascular complications in a health district of the UK. Diabet Med 2010 27 : 673 678.
11. Anonymous. Glitazones in type 2 diabetes: an update. Drug Ther Bull 2008 46 : 25 29.
12. Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008 15 : 321 325.
13. Institut für Qualität und Wirtschaftlichkeit. Website. Available at http://www.iqwig.de/ Last accessed 11 June 2009.
14. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type2 diabetes. Diabetologia 2009 52 : 1766 1777.
15. Currie CJ, Peters JR, Tynan A, Evans M, Heine R, Bracco AL et al. Survival in people with type 2 diabetes as a function of HbA1c: a non-linear association. Lancet 2010 375 : 481 489.
16. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2005 2 : CD005060.
17. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 2471.
18. Nathan DM. Rosiglitazone and cardiotoxicity - weighing the evidence. N Engl J Med 2007 357 : 64 66.
19. Currie CJ, Gale EAM, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med 2010 in press ].